Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine
- Registration Number
- NCT00564057
- Lead Sponsor
- Università degli Studi dell'Insubria
- Brief Summary
Human immunodeficiency virus infection and highly active antiretroviral therapy (HAART) are associated with an increased risk of cardiovascular disease: a wide range of alterations in lipid and glucose metabolism has been increasingly recognized in HIV patients treated with HAART. Few data are available on the effects of antihypertensive treatment on cardiac morpho-functional characteristics and metabolic parameters in HIV patients. Aim of the study is to assess the effects of chronic therapy with angiotensin receptor blocker(candesartan)or calcium channel blocker (lercanidipine)on metabolic profile and cardiac remodelling in HIV hypertensive patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- HIV infection
- office blood pressure > 140/90 mmHg
- no antihypertensive treatment
- good quality echocardiogram
Exclusion Criteria
- cardiovascular diseases
- hypothyroidism
- diabetes
- secondary hypertension
- hepatic and renal failure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 candesartan candesartan 8-16 mg once daily 2 lercanidipine lercanidipine 10-20 mg once daily
- Primary Outcome Measures
Name Time Method metabolic profile one year morpho-functional left ventricle characteristics one year
- Secondary Outcome Measures
Name Time Method systolic and diastolic blood pressure one year
Trial Locations
- Locations (1)
University of Insubria, Department of Clinical Medicine
🇮🇹Varese, Italy